Research advances in Janus kinase inhibitors for immune checkpoint inhibitors-related myocarditis
- 1Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Abstract
Immune checkpoint inhibitor-related myocarditis (ICIM) is a rare yet potentially lethal complication of immune checkpoint inhibitor (ICI) therapy, which severely impacts patient prognosis and therapeutic efficacy. With the widespread application of immunotherapy, ICIM has attracted significant attention from clinicians and researchers. However, its underlying pathogenesis remains to be fully elucidated, its clinical manifestations lack specificity, and management is frequently hampered by a dearth of effective, safe interventions. The Janus kinase (JAK) signaling pathway plays a critical role in regulating immune and inflammatory responses. JAK inhibitors exert immunomodulatory effects by blocking the JAK-STAT signaling pathway and have been utilized to treat a spectrum of immune-mediated disorders, emerging as a promising therapeutic strategy for ICIM. Accumulating evidence suggests that JAK inhibition may improve clinical outcomes in patients with ICIM. This review summarizes the latest advancements in JAK inhibitors for ICIM, aiming to provide a theoretical foundation and guide the optimization of future therapeutic strategies and clinical decisions.
Related
- Rechallenge After Immune Checkpoint Inhibitors Myocarditis: Evidence and a Practical Framework
- Immune checkpoint inhibitors combined with VEGF/VEGFR-targeted therapy in microsatellite-stable advanced colorectal cancer: clinical advances and the potential for immune-sensitive tumor conversion
- Small-molecule inhibitors and checkpoint inhibitors in KRAS G12C NSCLC: balancing efficacy and toxicity.
- Editorial: Predictive biomarkers to immune checkpoint inhibitors in lung cancer
- Evidence for Dose Optimization of Immune Checkpoint Inhibitors.
BibTeX
@article{leng2026research,
title = {{Research advances in Janus kinase inhibitors for immune checkpoint inhibitors-related myocarditis}},
author = {Jing Leng and Chenyu Wang and Chunmei Bai},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1857298},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1857298/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Research advances in Janus kinase inhibitors for immune checkpoint inhibitors-related myocarditis
AU - Jing Leng
AU - Chenyu Wang
AU - Chunmei Bai
PY - 2026
DA - 2026/10/20
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1857298
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1857298/full
AB - Immune checkpoint inhibitor-related myocarditis (ICIM) is a rare yet potentially lethal complication of immune checkpoint inhibitor (ICI) therapy, which severely impacts patient prognosis and therapeutic efficacy. With the widespread application of immunotherapy, ICIM has attracted significant attention from clinicians and researchers. However, its underlying pathogenesis remains to be fully elucidated, its clinical manifestations lack specificity, and management is frequently hampered by a dearth of effective, safe interventions. The Janus kinase (JAK) signaling pathway plays a critical role in regulating immune and inflammatory responses. JAK inhibitors exert immunomodulatory effects by blocking the JAK-STAT signaling pathway and have been utilized to treat a spectrum of immune-mediated disorders, emerging as a promising therapeutic strategy for ICIM. Accumulating evidence suggests that JAK inhibition may improve clinical outcomes in patients with ICIM. This review summarizes the latest advancements in JAK inhibitors for ICIM, aiming to provide a theoretical foundation and guide the optimization of future therapeutic strategies and clinical decisions.
SN - 1664-3224
ER -